TY - JOUR
T1 - Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications
AU - Akombaetwa, Nakamwi
AU - Ilangala, Ange B.
AU - Thom, Lorraine
AU - Memvanga, Patrick B.
AU - Witika, Bwalya Angel
AU - Buya, Aristote B.
N1 - Funding Information:
The APC was funded by Sefako Makgatho Health Sciences University.
Funding Information:
The authors would like to acknowledge Sefako Makgatho Health Sciences University for the payment of APC. ABI would like to acknowledge the support receive from le Fonds de la Recherche Scientifique (FRS-FNRS-Belgium. Credit n° 7651320F). PBM would like to thank the support from the Institut de la Francophonie pour le Développement Durable (IFDD/Canada)/Projet de Déploiement des Technologies et Innovations Environnemen-tales (PDTIE) funded by the Organisation internationale de la Francophonie (OIF), the Organisation of African, Caribbean and Pacific States (OACPS) and the European Union (EU) (FED/2020/421-370).
Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - Skin delivery is an exciting and challenging field. It is a promising approach for effective drug delivery due to its ease of administration, ease of handling, high flexibility, controlled release, prolonged therapeutic effect, adaptability, and many other advantages. The main associated challenge, however, is low skin permeability. The skin is a healthy barrier that serves as the body’s primary defence mechanism against foreign particles. New advances in skin delivery (both topical and transdermal) depend on overcoming the challenges associated with drug molecule permeation and skin irritation. These limitations can be overcome by employing new approaches such as lipid nanosystems. Due to their advantages (such as easy scaling, low cost, and remarkable stability) these systems have attracted interest from the scientific community. However, for a successful formulation, several factors including particle size, surface charge, components, etc. have to be understood and controlled. This review provided a brief overview of the structure of the skin as well as the different pathways of nanoparticle penetration. In addition, the main factors influencing the penetration of nanoparticles have been highlighted. Applications of lipid nanosystems for dermal and transdermal delivery, as well as regulatory aspects, were critically discussed.
AB - Skin delivery is an exciting and challenging field. It is a promising approach for effective drug delivery due to its ease of administration, ease of handling, high flexibility, controlled release, prolonged therapeutic effect, adaptability, and many other advantages. The main associated challenge, however, is low skin permeability. The skin is a healthy barrier that serves as the body’s primary defence mechanism against foreign particles. New advances in skin delivery (both topical and transdermal) depend on overcoming the challenges associated with drug molecule permeation and skin irritation. These limitations can be overcome by employing new approaches such as lipid nanosystems. Due to their advantages (such as easy scaling, low cost, and remarkable stability) these systems have attracted interest from the scientific community. However, for a successful formulation, several factors including particle size, surface charge, components, etc. have to be understood and controlled. This review provided a brief overview of the structure of the skin as well as the different pathways of nanoparticle penetration. In addition, the main factors influencing the penetration of nanoparticles have been highlighted. Applications of lipid nanosystems for dermal and transdermal delivery, as well as regulatory aspects, were critically discussed.
KW - dermal delivery
KW - lipid nanosystems
KW - nanoparticles
KW - targeted delivery
KW - transdermal delivery
UR - http://www.scopus.com/inward/record.url?scp=85149143041&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics15020656
DO - 10.3390/pharmaceutics15020656
M3 - Review article
C2 - 36839978
AN - SCOPUS:85149143041
SN - 1999-4923
VL - 15
JO - Pharmaceutics
JF - Pharmaceutics
IS - 2
M1 - 656
ER -